AcuCort AB (ACUC.ST)
SEK 0.73
(2.11%)
SEK 0.73
(2.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -19.24 Million SEK | -12.01% |
| 2022 | -17.18 Million SEK | 52.08% |
| 2021 | -35.85 Million SEK | -49.57% |
| 2020 | -23.96 Million SEK | 29.59% |
| 2019 | -34.04 Million SEK | -227.02% |
| 2018 | -10.41 Million SEK | 13.96% |
| 2017 | -12.09 Million SEK | -230.67% |
| 2016 | -3.65 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.73 Million SEK | -109.5% |
| 2024 Q1 | -5.59 Million SEK | 70.91% |
| 2023 Q3 | -7.02 Million SEK | -20.79% |
| 2023 Q4 | -19.24 Million SEK | -173.97% |
| 2023 FY | -19.24 Million SEK | -12.01% |
| 2023 Q2 | -5.81 Million SEK | 42.2% |
| 2023 Q1 | -10.06 Million SEK | 41.44% |
| 2022 Q3 | -21.27 Million SEK | 15.6% |
| 2022 Q4 | -17.18 Million SEK | 19.23% |
| 2022 Q2 | -25.2 Million SEK | 15.6% |
| 2022 Q1 | -29.86 Million SEK | 16.71% |
| 2021 Q4 | -35.85 Million SEK | -149.09% |
| 2021 Q3 | -14.39 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 33.869% |
| BioGaia AB (publ) | -1.53 Billion SEK | 98.747% |
| Enzymatica AB (publ) | 17.73 Million SEK | 208.496% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | -236.61% |
| Gabather AB (publ) | -1.11 Million SEK | -1625.919% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 208.815% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 65.524% |
| Nanexa AB (publ) | -61.13 Million SEK | 68.523% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | -25.753% |
| ODI Pharma AB | -2.63 Million SEK | -629.518% |
| Orexo AB (publ) | 302.8 Million SEK | 106.355% |
| Probi AB (publ) | -275.85 Million SEK | 93.024% |
| Swedencare AB (publ) | 1.42 Billion SEK | 101.354% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.098% |
| Toleranzia AB | -17.45 Million SEK | -10.256% |
| Vivesto AB | -1.29 Million SEK | -1381.447% |